Despite decades of innovation in medical imaging, breast cancer and other soft tissue diseases remain difficult to detect noninvasively with sufficient precision. In the United States alone, approximately 1.5 million breast biopsies are performed each year, with up to 80% of those (1.2 million) ultimately diagnosed as benign. These unnecessary procedures contribute to over $6 billion in annual healthcare spending, a cost borne by both patients and payers. Meanwhile, delayed diagnoses due to inconclusive imaging result in an estimated 50,000 breast cancer patients annually whose treatment is postponed, increasing treatment costs and decreasing survival rates. For clinicians, unnecessary biopsies add strain to understaffed hospitals, with radiologist workloads nearly doubling and pathologist cas